Early Human Development
Volume 84, Issue 6 , Pages 375-379 , June 2008

The plasma angiotensin II level increases in very low-birth weight infants with neonatal chronic lung disease

Received 15 June 2007 ,Revised 17 September 2007 ,Accepted 7 October 2007.

References 

  1. Fiselier T, Monnens L, van Munster P, Jansen M, Peer P, Lijnen P. The renin–angiotensin-aldosterone system in infancy and childhood in basal conditions and after stimulation. Eur J Pediatr. 1984;143:18–24
  2. Miyawaki M, Okutani T, Higuchi R, Yoshikawa N. Plasma angiotensin II levels in the early neonatal period. Arch Dis Child. 2006;91:359–362
  3. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease: bronchopulmonary dysplasia. N Engl J Med. 1967;276:357–368
  4. Jobe AH. Antenatal factors and the development of bronchopulmonary dysplasia. Semin Neonatol. 2003;8:9–17
  5. Tremblay LN, Slutsky AS. Ventilator-induced injury: from barotraumas to biotrauma. Proc Assoc Am Physicians. 1998;110:482–488
  6. Philip AGS. Oxygen plus pressure plus time; the etiology of bronchopulmonary dysplasia. Pediatrics. 1975;55:44–50
  7. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33:613–621
  8. Volland H, Pradelles P, Ronco P, Azizi M, Simon D, Creminon C, et al. A solid-phase immobilized epitope immnoassay (SPIE-IA) permitting very sensitive and specific measurement of angiotensin II in plasma. J Immunol Methods. 1999;228:37–47
  9. Fiselier TJ, Lijnen P, Monnens L, van Munster P, Jansen M, Peer P. Levels of renin, angiotensin I and II, angiotensin-converting enzyme and aldosterone in infancy and childhood. Eur J Pediatr. 1983;141:3–7
  10. Broughton Pipkin F, Smales OR, O'Callaghan M. Renin and angiotensin levels in children. Arch Dis Child. 1981;56:298–302
  11. Sippell WG, Dorr HG, Bidlingmaier F, Knorr D. Plasma levels of aldosterone, corticosterone, 11-deoxycorticosterone, progesterone, 17-hydroxyprogesterone, cortisol, and cortisone during infancy and childhood. Pediatr Res. 1980;14:39–46
  12. Mattioli L, Zakheim RM, Mullis K, Molteni A. Angiotensin-I-converting enzyme activity in idiopathic respiratory distress syndrome of the newborn infant and in experimental alveolar hypoxia in mice. J Pediatr. 1975;87:97–101
  13. Bender JW, Davitt MK, Jose P. Angiotensin-I-converting enzyme activity in term and premature infants. Biol Neonate. 1978;34:19–23
  14. Ng PC, Lam CW, Lee CH, Ma KC, Fok TF, Chan IH, et al. Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed. 2004;89:F119–F126
  15. Watterberg KL, Gerdes JS, Cook KL. Impaired glucocorticoid synthesis in premature infants developing chronic lung disease. Pediatr Res. 2001;50:190–195
  16. Peltoniemi O, Kari MA, Heinonen K, Saarela T, Nikolajev K, Andersson S, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr. 2005;146:632–637
  17. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med. 2000;161:1999–2004
  18. Papp M, Li X, Zhuang J, Wang R, Uhal BD. Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol. 2002;282:L713–L718
  19. Kazzi SN, Quasney MW. Deletion allele of angiotensin-converting enzyme is associated with increased risk and severity of cronchopulmonary dysplasia. J Pediatr. 2005;147:818–822
  20. Stark AR. High-frequency oscillatory ventilation to prevent bronchopulmonary dysplasia—are we there yet?. N Engl J Med. 2002;347:682–684
  21. Courtney SE, Durand DJ, Asselin JM, Hudak ML, Aschner JL, Shoemaker CT. Neonatal ventilation study group high-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth weight infants. N Engl J Med. 2002;347:643–652
  22. Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, et al. United Kingdom Oscillation Study Group High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med. 2002;347:633–642
  23. Bhuta T, Ohlsson A. Systemic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch Dis Child. 1988;79:F26–F33
  24. Halliday HL, Patterson CC, Halahakoon CW. A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics. 2001;107:232–240
  25. Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R, et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics. 2001;107:217–221
  26. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. National Institute of Child Health and Human Development Neonatal Research Network Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Eng J Med. 2001;344:95–101
  27. Finer NN, Craft A, Vaucher YE, Clark RH, Sola A. Postnatal steroids: short term gain, long term pain?. J Pediatr. 2000;137:9

PII: S0378-3782(07)00199-5

doi: 10.1016/j.earlhumdev.2007.10.005

Early Human Development
Volume 84, Issue 6 , Pages 375-379 , June 2008

Article Tools

* Image Usage & Resolution